ACUTE MYELOID LEUKEMIA RECURRENT
Clinical trials for ACUTE MYELOID LEUKEMIA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA RECURRENT trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immune cell boost plus targeted drug shows promise in early AML trial
Disease control Recruiting nowThis early-phase study tests the safety of giving special immune cells (CIML NK cells) along with a standard drug (venetoclax) to adults with acute myeloid leukemia (AML). The treatment aims to help the body's natural killer cells fight leukemia more effectively. About 10 partici…
Matched conditions: ACUTE MYELOID LEUKEMIA RECURRENT
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 26, 2026 11:30 UTC
-
New combo therapy targets tough leukemia gene mutations
Disease control Recruiting nowThis early-stage study tests an experimental drug called ziftomenib added to usual treatments for acute myeloid leukemia (AML) in people with specific gene changes (NPM1 mutation or KMT2A rearrangement). About 420 adults with newly diagnosed or returning AML will receive ziftomen…
Matched conditions: ACUTE MYELOID LEUKEMIA RECURRENT
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 22, 2026 14:01 UTC